| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.082 | 0.05 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.05 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.066 | 0.05 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.098 | 0.05 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.05 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.077 | 0.05 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.06 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.069 | 0.06 |